Detalhe da pesquisa
1.
Rapid identification of seized controlled substances and related compounds by tandem mass spectrometry without chromatography.
Rapid Commun Mass Spectrom
; 30(7): 908-16, 2016 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26969933
2.
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Lancet HIV
; 11(3): e156-e166, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38417976
3.
The impact of a combined mentalisation-based therapy and therapeutic community programme for adolescents with borderline personality disorder traits on service utilisation in Western Australia.
Personal Ment Health
; 17(4): 300-312, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36960575
4.
Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19.
Infect Dis Now
; 53(7): 104760, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37454762
5.
Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays.
Genomics
; 96(1): 57-65, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20353815
6.
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
Antimicrob Agents Chemother
; 53(4): 1532-8, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19188387
7.
Explosive detection using a novel dielectric barrier discharge ionisation source for mass spectrometry.
J Mass Spectrom
; 53(3): 214-222, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29212136
8.
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
AIDS
; 21(11): 1449-55, 2007 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-17589191
9.
Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.
AIDS
; 20(10): 1401-6, 2006 Jun 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-16791014
10.
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
AIDS Res Hum Retroviruses
; 22(8): 749-56, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16910830
11.
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
AIDS
; 18(3): 572-4, 2004 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-15090815
12.
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.
Antivir Ther
; 9(3): 423-9, 2004 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15259905
13.
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.
J Antimicrob Chemother
; 55(4): 542-5, 2005 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15722388
14.
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
J Acquir Immune Defic Syndr
; 37(3): 1376-84, 2004 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15483467